Clinical trials: Relapsed Cancer
Leukemia
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia.
- Trial name
- NCT00002704
- Testing
- filgrastim, asparaginase, cyclophosphamide
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 156 people
- Sponsor
- National Cancer Institute (NCI)
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment.
- Conditions
- CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT03094611
- Testing
- Inotuzumab Ozogamicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Lymphocytic Leukemia
Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum tolerated dose (MTD) of liposomal annamycin and to evaluate the safety of liposomal annamycin in patients with refractory or relapsed…
- Trial name
- NCT00271063
- Testing
- Liposomal Annamycin
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Callisto Pharmaceuticals
Osteosarcoma, Ewing Sarcoma
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
The is a phase II, single arm, open-label, multi-site trial studying the combination of cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) given at the recommended phase 2…
- Conditions
- Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor
- Trial name
- NCT05302921
- Testing
- Cryoablation Therapy, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's National Research Institute
Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
T- cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy) has an increase in proteins in a specific pathway called the mTOR pathway within the cancer cells.
- Trial name
- ENCERT (NCT03328104)
- Testing
- Everolimus, Nelarabine, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
This project is a prospective, single-center, randomized controlled clinical study. The subjects were high-risk or relapsed/refractory AML or ALL patients aged ≤ 65 years diagnosed by bone marrow cell morphology, immunology…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy
- Trial name
- NCT06816134
- Testing
- TmBU conditioning Regimen, mBUCY conditioning regimen
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003758
- Testing
- cytarabine, idarubicin, allogeneic bone marrow transplantation
- Where
- 16 sites in Belgium, Croatia and 5 more
- Volunteers
- 60 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Metastasis, Spinal Tumors
Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)
The purpose of this study is to evaluate the efficacy of hypofractionated stereotactic radiation treatments (SBRT) on children, teenagers and young adults malignant tumors.
- Conditions
- Brain Metastasis, Spinal Tumors, Lung Tumors, Ependymoma
- Trial name
- SBRT (NCT02013297)
- Testing
- SBRT treatment
- Where
- 15 sites in France
- Volunteers
- 61 people
- Sponsor
- Centre Leon Berard
Brain and Central Nervous System Tumors, Neuroblastoma
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
RATIONALE: Drugs such as temsirolimus and valproic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT01204450
- Testing
- Temsirolimus, Valproic Acid
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
- Trial name
- NCT04052997
- Testing
- Camidanlumab Tesirine
- Where
- 73 sites in United States, Belgium and 9 more
- Volunteers
- 117 people
- Sponsor
- ADC Therapeutics S.A.
Kidney Cancer
Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002610
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 203 people
- Sponsor
- Children's Oncology Group
Acute Myelogenous Leukemia
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9 mg/m2 will be the maximum tested dose.
- Trial name
- NCT00044733
- Testing
- Mylotarg (gemtuzumab ozogamicin) Injection
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT04532268
- Testing
- Humanized CD19 CAR-T cells
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment.
- Trial name
- NCT07306832
- Testing
- Pivekimab Sunirine
- Where
- 14 sites in United States, Australia and 5 more
- Volunteers
- 18 people
- Sponsor
- AbbVie
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00512668
- Testing
- leuprolide acetate, goserelin acetate, bicalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06081478
- Testing
- CD19/CD22-bispecific CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Tongren Hospital
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.
- Trial name
- NCT02748135
- Testing
- TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg
- Where
- 10 sites in United States
- Volunteers
- 18 people
- Sponsor
- Oncurious NV
Hodgkin Disease, Non Hodgkin Lymphoma
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
This protocol is broken up into 2 portions to determine the maximum tolerated dose for treating patients with a type of lymph gland disease.
- Conditions
- Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma
- Trial name
- ALCI (NCT00062868)
- Testing
- LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C)
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- Baylor College of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.